Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Add-On Therapy, 2-Period Cross-Over Clinical Trial to Evaluate the Safety and Efficacy of MK5757 for the Treatment of Cognitive Impairment in Men With Schizophrenia

This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.

Inclusion Criteria:

• Patient is male between 21 and 55 years of age
• Duration of the illness must be longer than 1 year
• Patient's current antipsychotic medication regimen must be stable
• Patient is negative for selected drugs of abuse at Screening
• Must be in a stable living arrangement for at least 3 months prior to screening (not a homeless shelter)

Exclusion Criteria:

• Patient has mental retardation
• Undergone Electroconvulsive Therapy (ECT) treatment within 6 months prior to screening
• Has suicidal attempts or ideation within the last 12 months
• Patient has a history of alcohol/drug dependence within 1 year or alcohol/drug abuse within 12 months of starting the study